Sox2 Expression Marks Castration‐Resistant Progenitor Cells in the Adult Murine Prostate
Sign Up to like & getrecommendations! Published in 2019 at "STEM CELLS"
DOI: 10.1002/stem.2987
Abstract: Identification of defined epithelial cell populations with progenitor properties is critical for understanding prostatic development and disease. Here, we demonstrate that Sox2 expression is enriched in the epithelial cells of the proximal prostate adjacent to… read more here.
Keywords: prostate; sox2 expression; castration; sox2 ... See more keywords
M0CRPC overview of management options
Sign Up to like & getrecommendations! Published in 2019 at "World Journal of Urology"
DOI: 10.1007/s00345-019-02997-z
Abstract: Though prostate cancer usually responds to androgen deprivation therapy (ADT) in the beginning, the majority of prostate cancers will develop castration resistance over time. The androgen receptor (AR) pathway is often found to be activated… read more here.
Keywords: m0crpc overview; management options; urology; castration ... See more keywords
Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain
Sign Up to like & getrecommendations! Published in 2020 at "Cell Biology and Toxicology"
DOI: 10.1007/s10565-020-09511-x
Abstract: Androgen deprivation therapy (ADT) via surgical or chemical castration frequently fails to halt lethal castration-resistant prostate cancer (CRPC), which is induced by multiple mechanisms involving constitutive androgen receptor (AR) splice variants, AR mutation, and/or de… read more here.
Keywords: qw07; androgen; prostate cancer; compound ... See more keywords
Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223
Sign Up to like & getrecommendations! Published in 2017 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-017-1785-0
Abstract: Despite the improvement provided by androgenic suppression in the treatment of prostate cancer, most of tumors develop resistance to castration. However, new therapies have demonstrated an increase in patient survival such as radium-223 (Ra-223), an… read more here.
Keywords: castration; treatment; radium 223; prostate cancer ... See more keywords
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
Sign Up to like & getrecommendations! Published in 2020 at "Advances in Therapy"
DOI: 10.1007/s12325-020-01260-x
Abstract: Introduction Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naïve metastatic castration-resistant PC (mCRPC) treated with… read more here.
Keywords: cause; enzalutamide abiraterone; treated enzalutamide; castration ... See more keywords
Metalloproteinase 11, potential marker and molecular target in advanced and castration-resistant prostate cancer. Culture study of peritumoral fibroblasts.
Sign Up to like & getrecommendations! Published in 2017 at "Actas urologicas espanolas"
DOI: 10.1016/j.acuro.2016.12.001
Abstract: OBJECTIVE To analyze the expression of metalloprotein 11 (MMP11) in cultured fibroblasts obtained from human prostate tumors with different clinical and pathological characteristics. MATERIAL AND METHODS For this study we analyzed samples of transrectal prostate… read more here.
Keywords: prostate; metalloproteinase potential; expression; castration ... See more keywords
Systemic treatment for metastatic prostate cancer
Sign Up to like & getrecommendations! Published in 2019 at "Asian Journal of Urology"
DOI: 10.1016/j.ajur.2019.02.002
Abstract: The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy (docetaxel,… read more here.
Keywords: prostate; metastatic prostate; treatment; prostate cancer ... See more keywords
GPER1 in sand rat epididymis: Effects of seasonal variations, castration and efferent ducts ligation.
Sign Up to like & getrecommendations! Published in 2017 at "Animal reproduction science"
DOI: 10.1016/j.anireprosci.2017.06.012
Abstract: Estrogen plays a crucial role in regulating epididymal function and development. Estrogen signaling is mediated via two main receptors essentially involved in the genomic regulating pathway: ERα and ERβ. Recent studies revealed the contribution of… read more here.
Keywords: sand; efferent ducts; estrogen; gper1 ... See more keywords
Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Biochemical pharmacology"
DOI: 10.1016/j.bcp.2021.114765
Abstract: Prostate cancer (PCa) is one of the leading causes of cancer-related deaths in men. Although androgen deprivation therapies (ADT) and antiandrogens confer increased survival rates, most patients eventually develop castration resistant disease (CRPC). Previous studies… read more here.
Keywords: androgen; senescence; castration; cancer ... See more keywords
Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New‐Onset Metastatic Castration‐Resistant Prostate Cancer
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2018.03.006
Abstract: Micro‐Abstract The HSD3B1 (1245C) variant is predictive of response to ADT in castration sensitive prostate cancer (CSPC) and to ketoconazole in castration resistant prostate cancer (CRPC). We hypothesized that the HSD3B1 (1245C) variant would be… read more here.
Keywords: response; 1245c variant; prostate cancer; castration ... See more keywords
Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration.
Sign Up to like & getrecommendations! Published in 2018 at "European urology"
DOI: 10.1016/j.eururo.2018.01.039
Abstract: Luteinizing hormone–releasing hormone (LH-RH) agonists are the standard for androgen deprivation therapy (ADT) in patients with prostate cancer (PCa). The European Urology Association guideline on PCa [1] recommends serum testosterone measurement during ADT to assess… read more here.
Keywords: prostate cancer; testosterone; castration; urology ... See more keywords